Correction to: Understanding Immune Responses to Lassa Virus Infection and to Its Candidate Vaccines (Vaccines, (2022), 10, 10, (1668), 10.3390/vaccines10101668)

Hannah L Murphy, Hinh Ly

Research output: Contribution to journalComment/debatepeer-review

Abstract

The authors would like to make the following corrections to this published paper [1]. In the original publication [1], there was a mistake in the first column of Table 1, published as “INO-4500 (MV backbone)”. The corrected notation for this should be “INO-4500 (DNA-based vaccine)”. There was an error in a sentence in the first paragraph of Section 4.1. Measles Virus Platform, published as “The INO-4500 is a DNA-based vaccine candidate that expresses the LASV GPC and is based on the Schwarz strain of the measles virus (MV) [94,95]”, which should be changed to the following version: “The INO-4500 is a DNA-based vaccine candidate that expresses the LASV GPC [94,95]”. The first sentence in the second paragraph of Section 4.1, “In addition to INO-4500, another vaccine candidate has been developed using the Schwarz MV vaccine platform, MV-LASV (V182-001, MeV-NP)”, should be removed. The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Original languageEnglish (US)
Article number909
JournalVaccines
Volume12
Issue number8
DOIs
StatePublished - Aug 2024

Bibliographical note

Publisher Copyright:
© 2024 by the authors.

PubMed: MeSH publication types

  • Published Erratum

Fingerprint

Dive into the research topics of 'Correction to: Understanding Immune Responses to Lassa Virus Infection and to Its Candidate Vaccines (Vaccines, (2022), 10, 10, (1668), 10.3390/vaccines10101668)'. Together they form a unique fingerprint.

Cite this